ARTICLE SUMMARY:
Growing demand for insulin patch pumps in the US—a market currently dominated by Insulet and the Omnipod 5—has ignited a firestorm of activity among would-be competitors, including Medtronic, Tandem Diabetes Care, Roche, and embecta, along with innovative smaller companies such as PharmaSens, Modular Medical, and ViCentra—all aiming to shake up the status quo.
Competition in the insulin pump market is heating up as more companies aim for a spot in the fast-growing patch-pump segment, dominated in the US by Insulet and its Omnipod 5 (O5) automated insulin delivery (AID) system. (See “Diabetes Devices: All Eyes on Patch Pumps,” MedTech Strategist, January 19, 2023.) Thanks to the O5, Insulet is now capturing nearly 60% of new pump patients in the US (both type 1s and type 2s) and holds a more than 50% revenue market share, according to analysts, with year/year US Omnipod revenue growth near 35% in Q3 2023.
